Trump/Putin summit, UnitedHealth and Japan’s GDP - what’s moving markets
Pieris Pharmaceuticals Inc . (NASDAQ:PVLA) stock soared to a 52-week high, reaching a price level of $22.56, marking a significant milestone for the $247 million market cap biotechnology company. According to InvestingPro data, analysts see further upside potential with price targets ranging from $30 to $44. This peak reflects a robust year-over-year growth, with the stock experiencing an impressive 61.15% increase in value over the past year. Investors have shown increased confidence in Pieris Pharmaceuticals’ potential, as the company continues to make strides in its development of novel therapeutics. The company maintains a GREAT financial health score, though current valuations suggest the stock may be overvalued. The 52-week high serves as a testament to the company’s recent successes and the market’s optimistic outlook on its future endeavors. Discover 12 additional key insights about PVLA with an InvestingPro subscription.
In other recent news, Palvella Therapeutics has announced positive results from its Phase 2 study of QTORIN rapamycin for treating microcystic lymphatic malformations (microLMs), with 100% of participants showing significant improvement after a 12-week treatment period. The Phase 3 SELVA trial is underway, with topline data expected in the first quarter of 2026. The U.S. Food and Drug Administration has granted the trial Breakthrough Therapy, Fast Track, and Orphan Drug Designations, alongside an Orphan Product Grant of up to $2.6 million. In analyst activity, H.C. Wainwright has maintained a Buy rating for Palvella, setting a price target of $38, highlighting the potential of QTORIN rapamycin for cutaneous venous malformations (VMs). TD Cowen also initiated coverage with a Buy rating and a $44 target, citing optimism about the QTORIN platform’s ability to address rare genetic skin diseases. The analysts project that QTORIN rapamycin could achieve peak potential sales of approximately $956 million in the U.S. for Pachyonychia Congenita. Palvella’s ongoing trials aim to address significant unmet medical needs, with the potential to establish QTORIN rapamycin as a first-line standard of care for these conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.